![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Ariya Bio
Company Type: Therapeutics
Main focus: Development of genome editing therapies for haemoglobinopathies
Company stage: Pre-clinical
Diseases: Haemoglobinopathies
Genome-editing tool: CRISPR-Cas
Funding stage: Pre-seed
Location: Schlieren, Switzerland
Website: https://www.ariyabio.ch/
Pipeline:
Partners:
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Ariya_Bio_3eb3977af5_4b665aad33.png)
Ariya Bio is a pre-clinical stage company that focuses on developing new CRISPR-based cell and gene therapies for hereditary blood diseases. Their current programmes are focused on beta-haemoglobinopathies and alpha-thalassemia.